Cizzle presents at SYNLAB Innovation Symposium
Cizzle Biotechnology Holdings PLC
23 October 2026
REACH
23 October 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Cizzle Biotechnology presents at SYNLAB 12th Innovation Academy Symposium
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to highlight further industry engagement and the Company’s participation at a leading NHS partner’s symposium
Highlights
- Cizzle Biotechnology is participating in the SYNLAB 12th Innovation Academy Symposium on 5 November 2026
- Co-presentation at the symposium of technical evaluation studies of the Company’s CIZ1B biomarker test underway at the Christie Pathology Partnership, Manchester
- Communication of test improvements, as reported in peer-reviewed publication ‘The Journal of Applied Laboratory Medicine’
Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said
“I am delighted that Cizzle has been invited to present its latest improvements to the CIZ1B test to such a knowledgeable audience. The progress we have made this year has enabled precise and reproducible measurement of the CIZ1B lung cancer biomarker, using scalable reagents that will be the foundation of a future high-throughput test kit.”
The Company maintains a research and collaboration agreement with the University of York which supports the development of CIZ1B biomarker test improvements, and independent validation as a clinical assay for early-stage lung cancer.
Technical progress arising from the collaboration was recently reported in ‘A Molecular Tool Set for Measurement of Lung Cancer-Associated Protein Biomarker CIZ1B-FibA in Human Plasma’ Susanna F Rose, Joanna F Pearson, Lewis Byrom, Justin F X Ainscough, Dawn Coverley The Journal of Applied Laboratory Medicine. The paper, which may be accessed via: https://doi.org/10.1093/jalm/jfag124, evidences accuracy and reproducibility standards for the CIZ1B biomarker test that meet those required by major healthcare service providers.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited (Financial Adviser) |
+44(0) 20 3328 5656 |
|
John Depasquale (Corporate Finance)
|
|
|
Zeus (Corporate Broker) James Hornigold, Alex Slater (Investment Banking) Nick Searle (ECM) |
+44(0) 20 3829 5000 |
|
IFC Advisory Limited (Financial PR & IR) |
+44(0) 20 3934 6632 |
|
Tim Metcalfe |
|
|
Florence Staton
|
|
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer. In June 2026, the test was successfully accredited for use in the United States under the Clinical Laboratory Improvement Amendments (CLIA) process, providing a regulated laboratory route to market that enables licensed US healthcare providers to order the test.
Cizzle has entered into commercial royalty-bearing licensing arrangements covering North America and the Caribbean and is working with commercial partners and centres of excellence in cancer care to support the adoption of its proprietary diagnostic technologies in the UK and elsewhere.
Cizzle was admitted to the Official List and Main Market of the London Stock Exchange in May 2021.
For more information, please seehttps://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
About SYNLAB UK & Ireland
SYNLAB UK & Ireland delivers high‑quality laboratory and diagnostic services, performing more than 65 million tests every year, from routine blood tests to advanced molecular and genetic analysis. With a team of more than 3,000 people it supports NHS and private user through four NHS services; The Christie Pathology Partnership in Manchester, SYNLA Essex, Southwest Pathology Services in Somerset, and Synnovis, its partnership with Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.
For more information, please seehttps://synlab.co.uk/
About The Christie Pathology Partnership
The Christie Pathology partnership (CPP) is a joint venture between SYNLAB UK & Ireland and The Christie NHS Foundation Trust in Manchester. The partnership was established in June 2014, and renewed in May 2025. It will see significant invest from SYNLAB into new state-of-the-art laboratories for increased capacity, resilience, and research funding. CPP is UKAS Accredited and delivers specialist oncology and clinical pathology diagnostics to the NHS, and the private pay market, serving a population of about 3.2 million people in and around Manchester.
For more information, please seehttps://synlab.co.uk/cpp/
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.